BEAM-302 shows durable AATD correction with favorable safety profile
BEAM-302 demonstrated durable, functional correction of AATD, with a favorable safety profile. In the 60 mg group, all patients maintained protective AAT levels, while the pivotal global cohort is enrolling rapidly.
BEAM-302 showed durable, functional correction of AATD with a favorable safety profile and all patients on 60 mg maintaining protective AAT levels. The pivotal global cohort is enrolling rapidly, with regulatory alignment for accelerated approval and a strong financial position supporting ongoing d…